EXEL

+ Watchlist + Portfolio

Exelixis, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $54.39
52-Week Range: $33.76 – $57.57
Market Cap: $13.30B
P/E (TTM): 16.88
EPS (TTM): 3.18
Dividend Yield: —

Advanced Metrics

Price/Book: 7.25
PEG Ratio: 2.56
Return on Equity: 44.39%
Return on Assets: 23.97%
Gross Margin: 96.48%
Operating Margin: 39.51%
Profit Margin: 35.33%
Current Ratio: 3.46
Debt/Equity: 0.09
Total Debt: $165.93M
Free Cash Flow: $739.72M
Revenue Growth: 10.60%
Earnings Growth: 26.20%
Enterprise Value: $12.80B

EXEL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.61B	$1.83B	$2.17B	$2.32B
Cost of Revenue	$57.91M	$72.55M	$76.22M	$83.70M
Gross Profit	$1.55B	$1.76B	$2.09B	$2.24B
Research & Development	$891.81M	$1.04B	$910.41M	$825.00M
Selling, General & Admin	$459.86M	$542.71M	$492.13M	$518.73M
Operating Expenses	$1.35B	$1.59B	$1.40B	$1.34B
Operating Income	$201.48M	$170.88M	$689.95M	$892.70M
EBITDA	$222.36M	$196.60M	$718.75M	$921.76M
Pretax Income	$234.35M	$257.52M	$681.64M	$941.21M
Income Tax	$52.07M	$49.76M	$160.37M	$158.64M
Net Income	$182.28M	$207.76M	$521.27M	$782.57M
Diluted EPS	0.56	0.65	1.76	2.78
Diluted Shares	324.56M	321.46M	296.13M	281.86M

EXEL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$501.19M	$262.99M	$217.37M	$482.49M
Receivables	$214.78M	$237.41M	$265.44M	$286.92M
Inventory	$33.30M	$17.32M	$22.39M	$21.69M
Current Assets	$1.62B	$1.32B	$1.47B	$1.44B
Total Assets	$3.07B	$2.94B	$2.95B	$2.84B
Current Liabilities	$324.36M	$394.28M	$403.77M	$405.64M
Total Debt	$190.17M	$189.94M	$190.82M	$173.04M
Total Liabilities	$583.06M	$678.45M	$703.49M	$683.10M
Retained Earnings	-$34.23M	-$173.35M	-$98.65M	-$76.83M
Shareholders' Equity	$2.49B	$2.26B	$2.24B	$2.16B
Working Capital	$1.29B	$923.68M	$1.06B	$1.04B

EXEL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$362.61M	$333.32M	$699.97M	$884.27M
Capital Expenditure	-$138.46M	-$162.97M	-$66.19M	-$39.93M
Free Cash Flow	$224.16M	$170.35M	$633.79M	$844.34M
Depreciation & Amortisation	$20.88M	$25.72M	$28.80M	$29.05M
Stock-Based Compensation	$107.57M	$106.34M	$93.84M	$112.98M
Investing Cash Flow	-$524.41M	-$26.95M	-$116.78M	$350.44M
Financing Cash Flow	$586.00K	-$546.05M	-$628.81M	-$969.59M
Share Repurchases	$0.00	-$550.38M	-$652.03M	-$947.51M
Net Change in Cash	-$161.21M	-$239.68M	-$45.62M	$265.11M

EXEL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$555.45M	$568.26M	$597.75M	$598.66M	$610.81M
Cost of Revenue	$19.17M	$19.47M	$18.57M	$26.48M	$19.95M
Gross Profit	$536.27M	$548.79M	$579.18M	$572.18M	$590.86M
Research & Development	$212.23M	$200.36M	$199.16M	$213.25M	$199.92M
Selling, General & Admin	$137.18M	$134.86M	$123.66M	$123.02M	$139.60M
Operating Expenses	$349.42M	$335.21M	$322.82M	$336.27M	$339.52M
Operating Income	$186.86M	$213.58M	$256.36M	$235.91M	$251.34M
EBITDA	$194.20M	$220.92M	$263.78M	$242.86M	$258.29M
Pretax Income	$205.69M	$230.41M	$252.41M	$252.69M	$267.69M
Income Tax	$46.07M	$45.57M	$58.84M	$8.16M	$57.22M
Net Income	$159.62M	$184.85M	$193.58M	$244.53M	$210.47M
Diluted EPS	0.55	0.65	0.69	0.88	0.79
Diluted Shares	288.18M	284.39M	278.54M	276.35M	267.32M

EXEL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$183.75M	$164.43M	$376.30M	$482.49M	$226.15M
Receivables	$281.64M	$292.35M	$309.73M	$286.92M	$328.95M
Inventory	$24.85M	$23.48M	$27.40M	$21.69M	$26.61M
Current Assets	$1.40B	$1.18B	$1.40B	$1.44B	$1.21B
Total Assets	$2.84B	$2.68B	$2.82B	$2.84B	$2.59B
Current Liabilities	$399.10M	$336.11M	$373.78M	$405.64M	$370.98M
Total Debt	$187.13M	$179.84M	$176.46M	$173.04M	$169.54M
Total Liabilities	$706.22M	$644.54M	$662.85M	$683.10M	$657.85M
Retained Earnings	-$163.29M	-$219.54M	-$106.06M	-$76.83M	-$215.79M
Shareholders' Equity	$2.13B	$2.03B	$2.16B	$2.16B	$1.94B
Working Capital	$997.40M	$844.65M	$1.03B	$1.04B	$837.66M

EXEL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$211.44M	$48.99M	$290.32M	$333.51M	$251.84M
Capital Expenditure	-$22.45M	-$3.59M	-$6.73M	-$7.16M	-$2.03M
Free Cash Flow	$188.99M	$45.41M	$283.59M	$326.36M	$249.81M
Depreciation & Amortisation	$7.34M	$7.34M	$7.42M	$6.95M	$6.95M
Stock-Based Compensation	$25.93M	$36.07M	$30.89M	$20.10M	$29.05M
Investing Cash Flow	$49.76M	$248.03M	$25.41M	$27.24M	-$51.07M
Financing Cash Flow	-$294.82M	-$316.34M	-$103.86M	-$254.57M	-$457.11M
Share Repurchases	-$283.93M	-$301.92M	-$104.03M	-$257.62M	-$430.35M
Net Change in Cash	-$33.62M	-$19.32M	$211.87M	$106.19M	-$256.34M

Market Snapshot

About

Exelixis, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of new medicines for cancer treatment. The company's flagship product is CABOMETYX (cabozantinib), a kinase inhibitor approved for advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Exelixis has built a diverse pipeline of oncology compounds targeting various cancer types through both internal research and strategic partnerships. The company has collaborations with major pharmaceutical firms including Ipsen, Takeda, and Genentech to develop and commercialize its therapies globally.